• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form POS AM filed by Vincerx Pharma Inc.

    5/1/25 5:08:42 PM ET
    $VINC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VINC alert in real time by email
    POS AM 1 d837958dposam.htm POS AM POS AM

    As filed with the Securities and Exchange Commission on May 1, 2025

    Registration No. 333-260246

     

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    Post-Effective Amendment No. 2

    to

    Form S-1 on

    Form S-3

    Registration Statement

    Under

    The Securities Act of 1933

     

     

    Vincerx Pharma, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   2834   83-3197402

    (State or other jurisdiction of

    incorporation or organization)

     

    (Primary Standard Industrial

    Classification Code Number)

     

    (I.R.S. Employer

    Identification No.)

    1825 S. Grant Street

    San Mateo, California 94402

    (650) 800-6676

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

     

     

    Raquel E. Izumi

    Acting Chief Executive Officer

    Vincerx Pharma, Inc.

    1825 S. Grant Street

    San Mateo, California 94402

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

    Copies to:

    Gabriella A. Lombardi

    Julie Park

    Pillsbury Winthrop Shaw Pittman LLP

    2550 Hanover Street

    Palo Alto, CA 94304

    (650) 233-4500

     

     

    Approximate date of commencement of proposed sale to the public: This post-effective amendment is being filed to deregister the unsold securities previously registered under this Registration Statement.

    If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box: ☐

    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box: ☐

    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

    If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

    If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐

    If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
         Emerging growth company   ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of Securities Act. ☐

     

     
     


    DEREGISTRATION OF UNSOLD SECURITIES

    This Post-Effective Amendment (this “Post-Effective Amendment”), filed by Vincerx Pharma, Inc., a Delaware corporation (the “Registrant”), relates to the Registration Statement on Form S-3 (File No. 333-260246) filed by the Registrant with the Securities and Exchange Commission (the “SEC”) on October 14, 2021 and declared effective on October 25, 2021 (the “Registration Statement”). The Registration Statement was filed with respect to the offer and resale by the selling stockholders named therein from time to time of shares of common stock. The number of shares of common stock originally registered have not been adjusted to reflect the one-for-twenty (1-for-20) reverse stock split that became effective on January 27, 2025.

    On April 28, 2025, the Registrant filed a Notification of Removal From Listing and/or Registration on Form 25 with the SEC to delist its common stock from The Nasdaq Stock Market LLC and to deregister the common stock under Section 12(b) of the Securities Exchange Act of 1934. As previously disclosed in a Current Report on Form 8-K filed with the SEC on April 17, 2025, the board of directors of the Registrant approved the dissolution and liquidation of the Registrant pursuant to a plan of dissolution, subject to the approval of the Registrant’s stockholders. Accordingly, the Registrant is terminating all offerings of its securities pursuant to existing registration statements under the Securities Act of 1933, including the Registration Statement.

    Pursuant to the undertaking made by the Registrant in the Registration Statement to remove from registration by means of a post-effective amendment any of the securities that had been registered for issuance that remain unsold at the termination of the offering, the Registrant is filing this Post-Effective Amendment to terminate the effectiveness of such Registration Statement and to deregister, as of the effectiveness of this Post-Effective Amendment, any and all shares of common stock registered thereunder that remain unsold as of the effectiveness date. As a result of this deregistration and upon the effectiveness of this Post-Effective Amendment, no shares of common stock will remain registered pursuant to the Registration Statement.


    SIGNATURE

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this Post-Effective Amendment to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Mateo, State of California, on May 1, 2025.

     

    VINCERX PHARMA, INC.
    By:  

    /s/ Raquel E. Izumi

     

    Raquel E. Izumi

    Acting Chief Executive Officer

    Note: No other person is required to sign this Post-Effective Amendment in reliance upon Rule 478 under the Securities Act of 1933.

    Get the next $VINC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VINC

    DatePrice TargetRatingAnalyst
    1/14/2022$25.00Buy
    HC Wainwright & Co.
    12/23/2021$25.00Overweight
    Cantor Fitzgerald
    11/1/2021$24.00Outperform
    SVB Leerink
    9/13/2021$30.00Buy
    Laidlaw
    8/25/2021$26.00Buy
    B. Riley Securities
    8/13/2021$33.00 → $30.00Buy
    Chardan Capital
    More analyst ratings

    $VINC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vincerx Pharma, Inc. Announces Additional Adjournment of Special Meeting - Urges Stockholders to Vote FOR Approval of Dissolution Proposal

    Revised Potential Distribution Range of $0.03 to $0.07 per sharebased on current estimates and assumptions Failure to approve Dissolution Proposal on a timely basis will result in continued operating costs and further reduce or eliminate any potential distributions to stockholders   SAN MATEO, Calif., July 16, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (OTC:VINC) today announced that the re-convened Special Meeting of Stockholders to consider a proposal to approve the liquidation and dissolution of Vincerx (the "Dissolution Proposal"), which was originally scheduled for earlier today, has again been adjourned, this time until 10:00 a.m., Pacific time, on August 27, 2025 via li

    7/16/25 4:05:00 PM ET
    $VINC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vincerx Pharma, Inc. Urges Stockholders to Vote FOR Approval of Dissolution Proposal and Announces Potential Range for Distributions to Stockholders

    Potential Distribution Range of $0.04 to $0.08 per share of outstanding stock based on current estimates and assumptions, including timely approval of Distribution Proposal Failure to approve Dissolution Proposal will reduce or eliminate any potential distributions to stockholders   SAN MATEO, Calif., July 07, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (OTC:VINC) today announced updated information regarding the Special Meeting of Stockholders of the Company (the "Special Meeting") to consider the proposal to approve the dissolution and liquidation of the Company pursuant to the Plan of Liquidation and Dissolution (the "Dissolution Proposal"). The Special Meeting was adjourned to 10:0

    7/7/25 4:05:00 PM ET
    $VINC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vincerx Pharma, Inc. Announces Adjournment of Special Meeting - Will Reconvene Meeting on July 16, 2025 to Secure Votes Needed to Approve Dissolution Proposal

    SAN MATEO, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (OTC:VINC) today announced that the Special Meeting of Stockholders to consider a proposal to approve the liquidation and dissolution of Vincerx (the "Dissolution Proposal"), which was originally scheduled for earlier today, has been adjourned until 10:00 a.m., Pacific time, on July 16, 2025 via live audio webcast at www.virtualshareholdermeeting.com/VINC2025SM2. The adjournment will allow Vincerx more time to solicit the votes needed to approve the Dissolution Proposal. Vincerx is urging ALL stockholders to vote IMMEDIATELY FOR the Dissolution Proposal. Vincerx's board of directors unanimously recommends that stoc

    6/18/25 4:05:00 PM ET
    $VINC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VINC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Haas Kevin claimed ownership of 42,776 shares (SEC Form 3)

    3 - Vincerx Pharma, Inc. (0001796129) (Issuer)

    1/6/25 4:29:47 PM ET
    $VINC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Officer Thomas Tom C

    4 - Vincerx Pharma, Inc. (0001796129) (Issuer)

    8/14/24 8:11:28 PM ET
    $VINC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Executive Officer Hamdy Ahmed Md

    4 - Vincerx Pharma, Inc. (0001796129) (Issuer)

    8/14/24 8:07:30 PM ET
    $VINC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VINC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright & Co. initiated coverage on Vincerx Pharma with a new price target

    HC Wainwright & Co. initiated coverage of Vincerx Pharma with a rating of Buy and set a new price target of $25.00

    1/14/22 6:06:29 AM ET
    $VINC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Vincerx Pharma with a new price target

    Cantor Fitzgerald initiated coverage of Vincerx Pharma with a rating of Overweight and set a new price target of $25.00

    12/23/21 6:37:41 AM ET
    $VINC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVB Leerink initiated coverage on Vincerx Pharma with a new price target

    SVB Leerink initiated coverage of Vincerx Pharma with a rating of Outperform and set a new price target of $24.00

    11/1/21 6:31:16 AM ET
    $VINC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VINC
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Vincerx Pharma Inc.

    SCHEDULE 13G/A - Vincerx Pharma, Inc. (0001796129) (Subject)

    7/29/25 5:55:43 PM ET
    $VINC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by Vincerx Pharma Inc.

    DEFA14A - Vincerx Pharma, Inc. (0001796129) (Filer)

    7/16/25 4:14:14 PM ET
    $VINC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by Vincerx Pharma Inc.

    DEFA14A - Vincerx Pharma, Inc. (0001796129) (Filer)

    7/7/25 4:27:01 PM ET
    $VINC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VINC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Vincerx Pharma Inc.

    SC 13G - Vincerx Pharma, Inc. (0001796129) (Subject)

    11/14/24 3:39:40 PM ET
    $VINC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Vincerx Pharma Inc.

    SC 13G/A - Vincerx Pharma, Inc. (0001796129) (Subject)

    11/14/24 11:57:03 AM ET
    $VINC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Vincerx Pharma Inc.

    SC 13G/A - Vincerx Pharma, Inc. (0001796129) (Subject)

    11/13/24 8:32:26 AM ET
    $VINC
    Biotechnology: Pharmaceutical Preparations
    Health Care